TG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated

MT Newswires Live

May 05, 2025

TG Therapeutics (TGTX) reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.

Analysts polled by FactSet expected $0.17.

Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.

Analysts surveyed by FactSet expected $117.9 million.

As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.

BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.

The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533083583"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533083583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533083583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-05 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533083583","market":"sh","top_or_hot":-1,"title":"TG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated","media":"MT Newswires Live","content":"<html><body><p> TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TGTX) reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.</p><p>Analysts polled by FactSet expected $0.17.</p><p>Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.</p><p>Analysts surveyed by FactSet expected $117.9 million.</p><p>As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.</p><p>BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.</p><p>The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-05 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TGTX) reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.</p><p>Analysts polled by FactSet expected $0.17.</p><p>Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.</p><p>Analysts surveyed by FactSet expected $117.9 million.</p><p>As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.</p><p>BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.</p><p>The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TG","symbol_name":"特里迪加","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2533083583","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533083583","pubTimestamp":1746445126,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TG Therapeutics  reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.Analysts polled by FactSet expected $0.17.Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.Analysts surveyed by FactSet expected $117.9 million.As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TG":"特里迪加","TGTX":"TG Therapeutics Inc."},"translate_title":"TG Therapeutics第一季度净利润波动，收入增长；2025年全年BRIUMVI收入指引更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1,"TGTX":1},"content_text":"TG Therapeutics (TGTX) reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.Analysts polled by FactSet expected $0.17.Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.Analysts surveyed by FactSet expected $117.9 million.As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}